Longeveron Inc (LGVN)

$1.63 +0.02 (1.24%)
Market Cap 24.03M
Revenue (ttm) 2.39M
Net Income (ttm) -15.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -668.20%
Debt to Equity Ratio 0.04
Volume 139,400
Avg Vol 278,056
Day's Range N/A - N/A
Shares Out 14.93M
Stochastic %K 89%
Beta 0.39
Analysts Strong Sell
Price Target $8.88

Latest News on LGVN

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 6 weeks ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 7 weeks ago

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:04 PM EST - 7 weeks ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 7 weeks ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Feb 18, 2025, 9:25 AM EST - 2 months ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 4 months ago

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 5 months ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:37 PM EST - 5 months ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 5 months ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 6 months ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 6 months ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 6 months ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 6 months ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 7 months ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 7, 2024, 9:05 AM EDT - 7 months ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:05 AM EDT - 7 months ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 26, 2024, 9:05 AM EDT - 7 months ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:05 PM EDT - 8 months ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:58 PM EDT - 9 months ago

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 28, 2024, 4:51 PM EDT - 9 months ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 19, 2024, 4:05 PM EDT - 9 months ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 10 months ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron stock opened 100% up on Wednesday: explore why

Jul 10, 2024, 11:38 AM EDT - 10 months ago

Longeveron stock opened 100% up on Wednesday: explore why

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Jul 10, 2024, 7:30 AM EDT - 10 months ago

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Neha Motwani Elected to Longeveron® Board of Directors

Jul 9, 2024, 9:00 AM EDT - 10 months ago

Neha Motwani Elected to Longeveron® Board of Directors

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Jul 8, 2024, 9:00 AM EDT - 10 months ago

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Jun 18, 2024, 4:48 PM EDT - 11 months ago

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Jun 17, 2024, 9:00 AM EDT - 11 months ago

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Jun 17, 2024, 8:38 AM EDT - 11 months ago

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Why has Longeveron stock tripled in two days?

Jun 13, 2024, 9:45 AM EDT - 11 months ago

Why has Longeveron stock tripled in two days?

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Jun 3, 2024, 9:00 AM EDT - 11 months ago

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® to Attend BIO International Convention 2024

May 28, 2024, 8:05 AM EDT - 11 months ago

Longeveron® to Attend BIO International Convention 2024

Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript

May 17, 2024, 11:08 PM EDT - 1 year ago

Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

Longeveron Announces Board of Directors Planned Transitions

May 10, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Board of Directors Planned Transitions

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

May 2, 2024, 8:03 AM EDT - 1 year ago

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Longeveron to Present at the Planet MicroCap Showcase

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the Planet MicroCap Showcase

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

Longeveron Announces Closing of $5.2 Million Public Offering

Apr 11, 2024, 5:17 PM EDT - 1 year ago

Longeveron Announces Closing of $5.2 Million Public Offering

Longeveron Announces Pricing of $5.25 Million Public Offering

Apr 8, 2024, 2:15 PM EDT - 1 year ago

Longeveron Announces Pricing of $5.25 Million Public Offering

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

Longeveron Announces 1-for-10 Reverse Stock Split

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Longeveron Announces 1-for-10 Reverse Stock Split

Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 9:56 PM EST - 1 year ago

Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Feb 27, 2024, 4:05 PM EST - 1 year ago

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024

Feb 21, 2024, 4:05 PM EST - 1 year ago

Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024

Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™

Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 22, 2023, 4:05 PM EST - 1 year ago

Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 21, 2023, 10:34 AM EST - 1 year ago

UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules